Pharma Giants Bet Big on FGF21: Over $11.7 Billion in Deals Signals New Therapeutic Frontier

　　【Pharmaceutical Network Industry Dynamics】Currently, a competition surrounding the R&D and commercialization of the FGF21 target has begun, with pharmaceutical company acquisitions heating up. According to rough data statistics, by 2025, the total transactions in the FGF21 space by overseas pharmaceutical companies have exceeded $11.7 billion, with the top three companies—Novo Nordisk, Roche, and GSK—having invested over $10.7 billion cumulatively within just six months.
 

In October this year, Novo Nordisk announced a high-value acquisition of Akero Therapeutics for $5.2 billion. The core asset of this acquisition is Akero's FGF21 analog efruxifermin, which is currently in Phase III clinical trials targeting severe liver scarring (i.e., cirrhosis) caused by MASH (a disease triggered by excessive fat accumulation in the liver).
 

Efruxifermin, as an FGF21-Fc fusion protein (human IgG1 Fc domain linked to a modified human FGF21), exhibits an extended half-life and enhanced receptor affinity compared to native human FGF21. On January 27, 2025, Akero announced the preliminary top-line results of SYMMETRY at Week 96. After 96 weeks of treatment, the proportion of patients in the 50mg high-dose group showing fibrosis improvement by more than 1 stage was 39%, while the ITT analysis showed 29%.
 

In September, Roche announced that it had agreed to acquire biotech company 89bio for up to $3.5 billion, gaining access to the FGF21 analog Pegozafermin. Pegozafermin is a key drug in the late-stage development pipeline of 89bio and is expected to become a significant therapy for treating moderate to severe Metabolic Associated Steatohepatitis (MASH). 89bio stated that this transaction underscores the potential of its investigational MASH candidate, Pegozafermin. According to consensus forecasts provided by FactSet, this drug is expected to start generating revenue in 2028, with annual sales projected to approach $2 billion by 2030.
 

In May, GSK announced the acquisition of Boston Pharmaceuticals' core asset, Efimosfermin alfa, for up to $2 billion. Efimosfermin alfa (formerly known as BOS-580, LLF580) is an engineered long-acting variant of human FGF21 with an extended half-life of 21 days, allowing for once-monthly dosing and currently in Phase III development. Mid-stage trial data for efimosfermin alfa showed that once-monthly injections could rapidly reverse liver fibrosis and halt its progression.
 

GSK stated that the deal significantly expands the company's liver disease portfolio, aiming to address both the fatty degeneration and virus-driven factors of liver diseases, offering multiple development options, with a potential first launch in 2029.
 

In 2025, leading pharmaceutical companies are continuously concluding massive deals in the FGF21 field, demonstrating the recognition of the clinical value of this target by pharmaceutical enterprises and reflecting the broad application prospects of the FGF21 target in the treatment of metabolic diseases. Data shows that FGF21 belongs to the endocrine FGF subfamily, with core functions in regulating glucose and lipid homeostasis as well as energy metabolism. The liver, as the primary source organ of FGF21 in the body, can improve hepatic lipid metabolism, reduce steatosis, and enhance glucose uptake in adipocytes through its action. Studies indicate that FGF21 can alleviate hepatocyte stress, inhibit hepatic steatosis, and delay MASH-related inflammation and fibrosis progression, making it one of the promising potential targets for MASH following GLP-1.
 

The scientific mechanism and therapeutic potential of the FGF21 target imply significant commercial value. As the fastest-growing metabolic liver disease globally, MASH is highly associated with obesity and type 2 diabetes. According to relevant reports, by 2030, the number of patients worldwide will reach 490 million, and the corresponding drug market size will climb to $32.2 billion.
 

It is reported that in this popular field, pharmaceutical companies in China are also actively laying out. Currently, domestic companies' layout of FGF21 mainly focuses on the development of multi-target drugs. The main companies include An Yuan Pharmaceuticals, Dongyangguang Pharmaceuticals, Zhengda Tianqing, and Huadong/Doer Biologics, etc.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.